U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06975813) titled 'Magnesium Sulfate and Trigger Points' on May 09.
Brief Summary: The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter &sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score meas...